TSHA - צמיחת הכנסות ב-12 חודשים נגררים tayshagtx.com

Taysha Gene Therapies is developing a closed network for treating rare CNS pathologies using AAV vectors; however, the binary nature of clinical trials and scaling complexities create payback risks. This chart of trailing 12-month sales volume versus year-over-year growth visualizes these contradictions, where the value of -13.00 describes the current level. Meanwhile, the humanitarian status of the research and the absence of geopolitical pressure guarantee stable development.
Taysha Corp (TSHA) - פילוחי מדדים ודוחות פיננסיים

For Taysha Gene Therapies (TSHA), which is developing unique treatments for CNS pathologies, the relative revenue growth over the last four quarters compared to the previous year serves as an indicator of the commercial scalability of its niche developments. This metric calculates the percentage change in total sales over the last twelve months relative to the same period last year, allowing investors to filter out market noise and assess the fundamental stability of the business.